Characteristics and circadian distribution of cardiac arrhythmias in patients with heart failure and sleep-disordered breathing

Omran, Hazem; Bitter, Thomas; Horstkotte, Dieter; Oldenburg, Olaf; Fox, Henrik

doi:10.1007/s00392-018-1269-4

Cited by 37 publications

(28 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Amongst behavioural interventions, slowing spontaneous breathing rate below 10 breaths/min has the potential to favourably affect CV regulation [39–42]. The use of slow breathing (SLOWB) technique has been shown to reduce dyspnoea, improve oxygen saturation and exercise tolerance in HF patients, acutely increase baroreflex gain and stability in patients with CV disease and a risk for sudden death [42–45].…”

Section: Introductionmentioning

confidence: 99%

Long-term effects of device-guided slow breathing in stable heart failure patients with reduced ejection fraction

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Long-term effects of device-guided slow breathing in stable heart failure patients with reduced ejection fraction

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Indeed the presence of sleep apnea is associated with a poor prognosis as well as therapy failure in several diseases such as neurological disorders, heart failure, cardiac arrhythmias, and hypertension [6][7][8][9][10][11]. Most importantly, sudden death has also been associated with nocturnal hypoxia [12,13]. While monitoring ventilation during sleep, it is important to assess the total number of apneas and hypopneas including their duration, and to distinguish the central, obstructive and mixed apneas according to their varying causes and treatments [14,15].…”

Section: Introductionmentioning

confidence: 99%

Validation of a new wearable device for type 3 sleep test without flowmeter

et al. 2021

View full text Add to dashboard Cite

Background Ventilation monitoring during sleep is performed by sleep test instrumentation that is uncomfortable for the patients due to the presence of the flowmeter. The objective of this study was to evaluate if an innovative type 3 wearable system, the X10X and X10Y, is able to correctly detect events of apnea and hypopnea and to classify the severity of sleep apnea without the use of a flowmeter. Methods 40 patients with sleep disordered breathing were analyzed by continuous and simultaneous recording of X10X and X10Y and another certified type 3 system, SOMNOtouch, used for comparison. Evaluation was performed in terms of quality of respiratory signals (scores from 1, lowest, to 5, highest), duration and classification of apneas, as well as identification and duration of hypopneas. Results 580 periods were evaluated. Mean quality assigned score was 3.37±1.42 and 3.25±1.35 for X10X and X10Y and SOMNOtouch, respectively. The agreement between the two systems was evaluated with grades 4 and 5 in 383 out of 580 cases. A high correlation (r2 = 0.921; p<0.001) was found between the AHI indexes obtained from the two systems. X10X and X10Y devices were able to correctly classify 72.3% of the obstructive apneas, 81% of the central apneas, 61.3% of the hypopneas, and 64.6% of the mixed apneas when compared to SOMNOtouch device. Conclusion The X10X and X10Y devices are able to provide a correct grading of sleep respiratory disorders without the need of a nasal cannula for respiratory flow measurement and can be considered as a type 3 sleep test device for screening tests.

show abstract

“…Sleep-disordered breathing (SDB), obstructive sleep apnea (OSA) in particular, is highly prevalent in patients with heart failure (HF) [1,2]. Epidemiological studies suggest that OSA is an independent risk factor for HF development and has a negative effect on prognosis in patients with HF [3][4][5]. OSA is characterized by repeated partial or complete collapse of the upper airway during sleep [6], accompanied by complete absence of airflow and paradoxical respiration with opposing respiratory movements of the thorax and abdomen [7].…”

Section: Introductionmentioning

confidence: 99%

Automatic positive airway pressure for obstructive sleep apnea in heart failure with reduced ejection fraction

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background Moderate-to-severe obstructive sleep apnea (OSA) is highly prevalent in heart failure patients with reduced left ventricular ejection fraction (HFrEF), and is associated with worsening cardiac function and increased mortality. Objectives The automatic positive airway pressure (APAP) trial tested the impact of APAP treatment on changes for the pre-specified endpoints: changes in peak oxygen uptake (peak VO 2 ), percent-predicted peak VO 2 and oxygen uptake at anaerobic threshold (VO 2 -AT). Methods This randomized, controlled pilot study included patients with chronic, stable HFrEF who had moderate-to-severe OSA. Patients were randomized 1:1 to either APAP (AutoSet™, ResMed) or nasal strips (control) for 6 months. Results 76 patients have been randomized and 58 had complete data for final analysis. There was a statistically significant change in the APAP intervention arm for the primary endpoint percent-predicted peak VO 2 in comparison to control (67 ± 17 to 73 ± 19%; p = 0.01). Additional primary endpoints peak VO 2 and VO 2 -AT showed a trend in increase in the APAP group. Moreover, there were significant improvements within the APAP group for hypoxemia, left ventricular function and quality of life from baseline to 6 months, but not within the control group (p = 0.001 and p = 0.037, respectively). Conclusion APAP intervention was shown to significantly improve outcome compared to control group, represented in percent-predicted peak VO 2 , an established surrogate marker for cardiovascular prognosis in HFrEF. APAP has additional beneficial effects on hypoxemia, cardiac function and quality of life.

show abstract

Characteristics and circadian distribution of cardiac arrhythmias in patients with heart failure and sleep-disordered breathing

Abstract: CSA was associated with VT occurrence irrespective of sleep/wake status in HFrEF patients, and independently predicted the occurrence of VT. This association may contribute to chances by which CSA increases sudden death risk in HFrEF patients.

Cited by 37 publications

References 40 publications

Long-term effects of device-guided slow breathing in stable heart failure patients with reduced ejection fraction

Long-term effects of device-guided slow breathing in stable heart failure patients with reduced ejection fraction

Validation of a new wearable device for type 3 sleep test without flowmeter

Automatic positive airway pressure for obstructive sleep apnea in heart failure with reduced ejection fraction

Contact Info

Product

Resources

About